New York applications ongoing until September 12th

Learn more about investing in Amaryllis Nucleics, Inc.

Our team will get back to you soon to follow up on your inquiry.
Lead Rounds?
Amaryllis Nucleics, Inc.
Democratizing RNA Sequencing
* Data source: Crunchbase
Founded
2016
Employees*
1-10
Funding to Date*
undisclosed
Website
amaryllisnucleics.com
Brad Townsley, PhD, CEO
It really helps that most of our customers are a lot like us. We’ve used RNA sequencing since its early days and know many of the issues people have using it. Fundamentally we get the end user since that used to be us.
The cost of DNA sequencing has dropped tremendously in the past decade but RNA sequencing has lagged

Amaryllis Nucleics took a laborious and complicated chemical process to enable RNA sequencing and reduced it to a kit that non-experts can use and can complete the task in hours, when it used to take days. With a more accurate process, as well, Amaryllis Nucleics is democratizing access to RNA sequencing and in turn, acclerating the speed at which genomics discoveries are made by researchers.